David Sutton

3.1k total citations
57 papers, 2.2k citations indexed

About

David Sutton is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David Sutton has authored 57 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 15 papers in Oncology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in David Sutton's work include Complement system in diseases (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Platelet Disorders and Treatments (9 papers). David Sutton is often cited by papers focused on Complement system in diseases (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Platelet Disorders and Treatments (9 papers). David Sutton collaborates with scholars based in Canada, United States and United Kingdom. David Sutton's co-authors include Rashmi Ravindran Nair, William F. Clark, G. Rock, Joseph Brandwein, Noel A. Buskard, Michael Crump, Kenneth H. Shumak, G. Rock, Jonathan Scott and James Sharpe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

David Sutton

56 papers receiving 2.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David Sutton 884 590 477 456 424 57 2.2k
Erhard Hiller 856 1.0× 353 0.6× 357 0.7× 298 0.7× 306 0.7× 96 2.0k
Dolors Tàssies 842 1.0× 578 1.0× 346 0.7× 284 0.6× 295 0.7× 117 3.0k
Jan‐Stephan Sanders 1.8k 2.0× 875 1.5× 264 0.6× 802 1.8× 848 2.0× 168 4.2k
Jennifer Schneiderman 732 0.8× 484 0.8× 92 0.2× 360 0.8× 180 0.4× 45 1.9k
Evarist Feliú 1.3k 1.5× 310 0.5× 675 1.4× 978 2.1× 682 1.6× 209 3.0k
Wolfgang Miesbach 1.7k 1.9× 288 0.5× 118 0.2× 371 0.8× 511 1.2× 192 3.2k
Lois Ayash 1.3k 1.5× 451 0.8× 401 0.8× 225 0.5× 1.3k 3.0× 119 2.6k
Nicholas Bandarenko 616 0.7× 697 1.2× 57 0.1× 321 0.7× 123 0.3× 36 1.9k
Enrico Pogliani 1.7k 1.9× 426 0.7× 412 0.9× 1.1k 2.3× 515 1.2× 75 2.9k
Alice Maniatis 1.4k 1.6× 264 0.4× 193 0.4× 413 0.9× 456 1.1× 52 2.4k

Countries citing papers authored by David Sutton

Since Specialization
Citations

This map shows the geographic impact of David Sutton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sutton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sutton more than expected).

Fields of papers citing papers by David Sutton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sutton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sutton. The network helps show where David Sutton may publish in the future.

Co-authorship network of co-authors of David Sutton

This figure shows the co-authorship network connecting the top 25 collaborators of David Sutton. A scholar is included among the top collaborators of David Sutton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sutton. David Sutton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ansolabehere, Stephen, et al.. (2025). City-Defined Neighborhood Boundaries in the United States. Scientific Data. 12(1). 1031–1031. 1 indexed citations
2.
Rock, G., William F. Clark, David R. Anderson, et al.. (2013). ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura. Thrombosis Research. 131(4). 308–312. 11 indexed citations
3.
Foley, S.R., Kathryn E. Webert, Donald M. Arnold, et al.. (2009). A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International. 75(112). S55–S58. 15 indexed citations
4.
Anderson, David R., William F. Clark, Pierre Leblond, et al.. (2005). Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.. Blood. 106(11). 3989–3989. 1 indexed citations
5.
Karkouti, Keyvan, W. Scott Beattie, Duminda N. Wijeysundera, et al.. (2004). Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score–matched case‐control analysis. Transfusion. 45(1). 26–34. 138 indexed citations
6.
Rock, G., Doris Neurath, David Sutton, et al.. (2004). The use of a bacteria detection system to evaluate bacterial contamination in PLT concentrates. Transfusion. 44(3). 337–342. 25 indexed citations
7.
Rock, G., et al.. (2003). The Canadian apheresis registry. Transfusion and Apheresis Science. 29(2). 167–177. 58 indexed citations
8.
Xenocostas, Anargyros, Cindy J. Wong, David Sutton, et al.. (2003). RBC transfusion requirements after allogeneic marrow transplantation: impact of the before‐transplant Hb level on transfusion and early survival. Transfusion. 43(3). 373–382. 30 indexed citations
9.
Sutton, David, et al.. (2000). The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. Journal of the American Academy of Dermatology. 43(6). 1058–1064. 70 indexed citations
10.
Kim, Joseph S., et al.. (1999). Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use. Archives of Internal Medicine. 159(3). 311–311. 25 indexed citations
11.
Rock, G., et al.. (1997). Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. Journal of Clinical Apheresis. 12(4). 165–169. 19 indexed citations
12.
Imrie, Kevin, B. Sheridan, Michael Crump, et al.. (1997). A Phase I Study of Interleukin-6 After Autologous Bone Marrow Transplantation for Patients with Poor Prognosis Hodgkin's Disease. Leukemia & lymphoma. 25(5-6). 555–563. 6 indexed citations
13.
Prince, H. Miles, Michael Crump, Kevin Imrie, et al.. (1996). Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Annals of Oncology. 7(10). 1043–1049. 23 indexed citations
14.
15.
Goss, Paul E., Ronald L. Burkes, Leona Rudinskas, et al.. (1995). A Phase II Trial of Prednisone, Oral Etoposide, and Novantrone (PEN) as Initial Treatment of Non-Hodgkin's Lymphoma in Elderly Patients. Leukemia & lymphoma. 18(1-2). 145–152. 21 indexed citations
16.
Sawka, Carol, Frances A. Shepherd, Joseph Brandwein, et al.. (1992). Treatment of AIDS-Related Non-Hodgkin's Lymphoma with a Twelve Week Chemotherapy Program. Leukemia & lymphoma. 8(3). 213–220. 28 indexed citations
17.
Crump, Michael, David Sutton, & Dominic Pantalony. (1991). Sezary syndrome in a patient with hairy cell leukemia in remission. Cancer. 68(4). 829–833. 5 indexed citations
18.
Goss, Paul E., Frances A. Shepherd, Jonathan Scott, et al.. (1991). Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Annals of Oncology. 2. 43–46. 19 indexed citations
19.
Sutton, David, et al.. (1989). Complications of plasma exchange. Transfusion. 29(2). 124–127. 162 indexed citations
20.
Grossman, Loren D., M. A. Baker, David Sutton, & J.H.N. Deck. (1983). Central nervous system toxicity of high‐dose cytosine arabinoside. Medical and Pediatric Oncology. 11(4). 246–250. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erhard Hiller Breakdown of academic impact, for papers by Dolors Tàssies Breakdown of academic impact, for papers by Jan‐Stephan Sanders Breakdown of academic impact, for papers by Jennifer Schneiderman Breakdown of academic impact, for papers by Evarist Feliú Breakdown of academic impact, for papers by Wolfgang Miesbach Breakdown of academic impact, for papers by Lois Ayash Breakdown of academic impact, for papers by Nicholas Bandarenko Breakdown of academic impact, for papers by Enrico Pogliani Breakdown of academic impact, for papers by Alice Maniatis
Rankless by CCL
2026